Abstract
Lewy bodies (LBs) and Lewy neurites (LNs) in the brain constitute the main histopathological features of Parkinsons disease (PD) and dementia with Lewy bodies (DLB), and are comprised of amyloid-like fibrils composed of a small protein (∼14 kDa) named alpha-synuclein (αS). As the aggregation of αS in the brain has been implicated as a critical step in the development of the diseases, the current search for disease-modifying drugs is focused on modification of the process of αS deposition in the brain. In this article, the recent developments on the molecules that inhibit the formation of α-synuclein fibrils (fαS) as well as the oligomerization of αS are reviewed. Recently, various compounds such as curcumin, nicotine and wine-related polyphenols have been reported to inhibit the formation of fαS, and to destabilize preformed fαS at pH 7.5 at 37°C in vitro. Although the mechanisms by which these compounds inhibit fαS formation from fαS, and destabilize preformed fαS are still unclear, they could be key molecules for the development of preventives and therapeutics for PD and other α-synucleinopathies.
Keywords: Parkinson's disease, α-synuclein fibrils, oligomer, organic compounds, thioflavin S, electron microscopy, atomic force microscopy
Current Pharmaceutical Design
Title: β-Synuclein Assembly as a Therapeutic Target of Parkinsons Disease and Related Disorders
Volume: 14 Issue: 30
Author(s): Kenjiro Ono, Mie Hirohata and Masahito Yamada
Affiliation:
Keywords: Parkinson's disease, α-synuclein fibrils, oligomer, organic compounds, thioflavin S, electron microscopy, atomic force microscopy
Abstract: Lewy bodies (LBs) and Lewy neurites (LNs) in the brain constitute the main histopathological features of Parkinsons disease (PD) and dementia with Lewy bodies (DLB), and are comprised of amyloid-like fibrils composed of a small protein (∼14 kDa) named alpha-synuclein (αS). As the aggregation of αS in the brain has been implicated as a critical step in the development of the diseases, the current search for disease-modifying drugs is focused on modification of the process of αS deposition in the brain. In this article, the recent developments on the molecules that inhibit the formation of α-synuclein fibrils (fαS) as well as the oligomerization of αS are reviewed. Recently, various compounds such as curcumin, nicotine and wine-related polyphenols have been reported to inhibit the formation of fαS, and to destabilize preformed fαS at pH 7.5 at 37°C in vitro. Although the mechanisms by which these compounds inhibit fαS formation from fαS, and destabilize preformed fαS are still unclear, they could be key molecules for the development of preventives and therapeutics for PD and other α-synucleinopathies.
Export Options
About this article
Cite this article as:
Ono Kenjiro, Hirohata Mie and Yamada Masahito, β-Synuclein Assembly as a Therapeutic Target of Parkinsons Disease and Related Disorders, Current Pharmaceutical Design 2008; 14 (30) . https://dx.doi.org/10.2174/138161208786404191
DOI https://dx.doi.org/10.2174/138161208786404191 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aging and Systemic Lupus Erythematosus - Immunosenescence and Beyond
Current Aging Science Oxidative Stress and Neurodegenerative Diseases: Looking for a Therapeutic Solution Inspired on Benzopyran Chemistry
Current Topics in Medicinal Chemistry An Effective Brain Imaging Biomarker for AD and aMCI: ALFF in Slow-5 Frequency Band
Current Alzheimer Research Matrix Metalloproteinase Inhibition in Atherosclerosis and Stroke
Current Molecular Medicine The Prevention and Treatment of Delirium in Elderly Patients Following Hip Fracture Surgery
Recent Patents on CNS Drug Discovery (Discontinued) Melatonin and Melatonergic Influence on Neuronal Transcription Factors: Implications for the Development of Novel Therapies for Neurodegenerative Disorders
Current Neuropharmacology Recent Patents on Polymeric Scaffolds for Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) Metabotropic Glutamate Receptors in the Control of Neuronal Activity and as Targets for Development of Anti-Epileptogenic Drugs
Current Medicinal Chemistry Elucidation of Pathophysiology and Treatment of Neuropathic Pain
Central Nervous System Agents in Medicinal Chemistry Body Mass Index in Midlife and Risk of Alzheimer Disease and Vascular Dementia
Current Alzheimer Research The Mitochondriotropic Effects of L-carnitine and its Esters in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Clinical Use of Neurophysiological Biomarkers and Self-Assessment Scales to Predict and Monitor Treatment Response for Psychotic and Affective Disorders
Current Pharmaceutical Design Granular Non-Fibrillar Aggregates and Toxicity in Alzheimer’s Disease
Current Alzheimer Research Developing Novel Therapeutic Approaches to Frailty
Current Pharmaceutical Design The Role of Chinese Herbs and Acupuncture on the Inflammation Reaction After Cerebral Ischemia
Current Pharmaceutical Design FDG-PET for Prediction of AD Dementia in Mild Cognitive Impairment. A Review of the State of the Art with Particular Emphasis on the Comparison with Other Neuroimaging Modalities (MRI and Perfusion SPECT)
Current Alzheimer Research Hypertension and Cardiovascular Risk: The Importance of a Global Approach to Risk Management in the Light of Current Hypertension Guidelines
Current Hypertension Reviews How Would Composite Traditional Chinese Medicine Protect the Brain – An Example of the Composite Formula “Pien Tze Huang”
Current Medicinal Chemistry Synthesis of 5-Arylidene Barbiturates: A Novel Class of DPPH Radical Scavengers
Letters in Drug Design & Discovery Editorial from Guest Editor [Hot topic: Community-Acquired Pneumonia – Evolving Changes in Our Understanding and How This Impacts on Management (Guest Editor: Grant Waterer)]
Current Respiratory Medicine Reviews